Aktienanalyse zu Cerus Corp (CERS)CERSCerus Corp

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Cerus Corp appears to be a good buy at the current price of $2.33 due to its recent revenue growth of 10% year-over-year in Q2 2026 and a positive analyst price target of $6.50, indicating significant upside potential. The RSI is at 54.69, suggesting that the stock is neither overbought nor oversold, which is a favorable position for a long-term investment. However, the main risk is the negative net income, which was -$2.94 million in Q2 2026, indicating ongoing losses that investors should monitor closely.

3 analysts cover CERS: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.